Logo image of CSCI

COSCIENS BIOPHARMA INC (CSCI) Stock Price, Quote, News and Overview

NASDAQ:CSCI - Nasdaq - CA22112H1010 - Common Stock - Currency: USD

2.72  -0.02 (-0.91%)

CSCI Quote, Performance and Key Statistics

COSCIENS BIOPHARMA INC

NASDAQ:CSCI (2/21/2025, 8:11:02 PM)

2.72

-0.02 (-0.91%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap10.28M
Shares3.78M
Float3.73M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO12-19 1995-12-19


CSCI short term performance overview.The bars show the price performance of CSCI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

CSCI long term performance overview.The bars show the price performance of CSCI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of CSCI is 2.72 USD. In the past month the price decreased by -5.39%.

COSCIENS BIOPHARMA INC / CSCI Daily stock chart

CSCI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About CSCI

Company Profile

CSCI logo image COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

Company Info

COSCIENS BIOPHARMA INC

C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53

TORONTO ONTARIO CA

Employees: 21

Company Website: https://www.zentaris.com/

Investor Relations: http://ir.aezsinc.com/

Phone: 18439003201

COSCIENS BIOPHARMA INC / CSCI FAQ

What is the stock price of COSCIENS BIOPHARMA INC today?

The current stock price of CSCI is 2.72 USD. The price decreased by -0.91% in the last trading session.


What is the ticker symbol for COSCIENS BIOPHARMA INC stock?

The exchange symbol of COSCIENS BIOPHARMA INC is CSCI and it is listed on the Nasdaq exchange.


On which exchange is CSCI stock listed?

CSCI stock is listed on the Nasdaq exchange.


What is COSCIENS BIOPHARMA INC worth?

COSCIENS BIOPHARMA INC (CSCI) has a market capitalization of 10.28M USD. This makes CSCI a Nano Cap stock.


How many employees does COSCIENS BIOPHARMA INC have?

COSCIENS BIOPHARMA INC (CSCI) currently has 21 employees.


What are the support and resistance levels for COSCIENS BIOPHARMA INC (CSCI) stock?

COSCIENS BIOPHARMA INC (CSCI) has a support level at 2.65 and a resistance level at 2.75. Check the full technical report for a detailed analysis of CSCI support and resistance levels.


Is COSCIENS BIOPHARMA INC (CSCI) expected to grow?

The Revenue of COSCIENS BIOPHARMA INC (CSCI) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the CSCI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy COSCIENS BIOPHARMA INC (CSCI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does COSCIENS BIOPHARMA INC (CSCI) stock pay dividends?

CSCI does not pay a dividend.


When does COSCIENS BIOPHARMA INC (CSCI) report earnings?

COSCIENS BIOPHARMA INC (CSCI) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of COSCIENS BIOPHARMA INC (CSCI)?

COSCIENS BIOPHARMA INC (CSCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11).


What is the Short Interest ratio of COSCIENS BIOPHARMA INC (CSCI) stock?

The outstanding short interest for COSCIENS BIOPHARMA INC (CSCI) is 0.06% of its float. Check the ownership tab for more information on the CSCI short interest.


CSCI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CSCI.


Chartmill TA Rating
Chartmill Setup Rating

CSCI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CSCI. CSCI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CSCI Financial Highlights

Over the last trailing twelve months CSCI reported a non-GAAP Earnings per Share(EPS) of -11. The EPS decreased by -274.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -32.47%
ROE -71.02%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%-117.95%
Sales Q2Q%N/A
EPS 1Y (TTM)-274.15%
Revenue 1Y (TTM)-7.05%

CSCI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CSCI. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for CSCI


Ownership
Inst Owners7.38%
Ins Owners1.24%
Short Float %0.06%
Short Ratio0.26
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y68.75%
Revenue Next Year-2.27%